News
PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback